An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus.
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2013
At a glance
- Drugs Aliskiren/valsartan (Primary) ; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms ViVID
- 10 Jun 2017 Biomarkers information updated
- 22 May 2012 Results presented at the 27th Annual Scientific Meeting of the American Society of Hypertension.
- 03 May 2012 Actual patient number 998 added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History